News
Kymera Therapeutics raises $250.8M in public offering to advance its innovative degrader medicines for immunological diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback